Epilepsy, Anterior Fronto-Polar
|
0.300 |
Biomarker
|
disease |
CTD_human |
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
|
18413482 |
2008 |
Epilepsy, Orbito-Frontal
|
0.300 |
Biomarker
|
disease |
CTD_human |
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
|
18413482 |
2008 |
Mental deficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
|
18413482 |
2008 |
Epilepsy
|
0.320 |
Biomarker
|
disease |
BEFREE |
SLC4A10 is the third SLC4 base transporter family member to be implicated in human cognition and epilepsy.
|
18413482 |
2008 |
Epilepsy
|
0.320 |
Biomarker
|
disease |
BEFREE |
This second region comprises about 3 Mb and contains the candidate gene SLC4A10, providing further support for the potential role of this gene in epilepsy.
|
21204806 |
2010 |
Intellectual Disability
|
0.310 |
Biomarker
|
group |
BEFREE |
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
|
18413482 |
2008 |
Schizophrenia
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Based on conjunctional FDR < 0.05, we identified 2 loci shared between SCZ and ICV implicating genes FOXO3 (rs10457180) and ITIH4 (rs4687658), 2 loci shared between SCZ and hippocampal volume implicating SLC4A10 (rs4664442) and SPATS2L (rs1653290), and 2 loci shared between SCZ and volume of putamen implicating DCC (rs4632195) and DLG2 (rs11233632).
|
29136250 |
2018 |
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
Hydrocephalus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Deferoxamine and solute carrier family 4 member 10 small interfering RNA improved cognitive and motor functions at 21 to 28 days post GMH and reduced cerebrospinal fluid production as well as the degree of hydrocephalus at 28 days after GMH.
|
29386206 |
2018 |
Mental Retardation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
|
18413482 |
2008 |
Gilles de la Tourette syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Finally, seven candidate disease genes were disrupted in five carriers with neurocognitive disabilities (SVOPL, SUSD1, TOX, NCALD, SLC4A10) and one XX-male carrier with Tourette syndrome (LYPD6, GPC5).
|
27862604 |
2017 |
Epilepsy, Complex Partial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
|
18413482 |
2008 |
Glaucoma, Primary Open Angle
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There was no association between common sequence variants in the AQP1 or SLC4A10 genes and POAG in the Caucasian population.
|
20101282 |
2010 |
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
XX males
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, seven candidate disease genes were disrupted in five carriers with neurocognitive disabilities (SVOPL, SUSD1, TOX, NCALD, SLC4A10) and one XX-male carrier with Tourette syndrome (LYPD6, GPC5).
|
27862604 |
2017 |
Chronic metabolic acidosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The sodium-driven chloride/bicarbonate exchanger NDCBE in rat brain is upregulated by chronic metabolic acidosis.
|
21195699 |
2011 |